FindTrial
Sign In

Dose finding study of TAK-438 in patients with reflux esophagitis (phase II study)

Dose finding study of TAK-438 in patients with reflux esophagitis (phase II study)

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220896
Enrollment
Unknown
Registered
2009-10-19
Start date
2009-10-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

investigational material(s) Generic name etc : TAK-438 INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Endoscopic diagnosis of grade A to D reflux esophagitis by LA classification at the start of the follow-up period (visit 1), etc.

Exclusion criteria

Exclusion criteria: 1. Complications that may affect the esophagus, history of esophageal radiotherapy or cryotherapy, or presence of corrosive or physiochemical trauma 2. History of surgery for reflux esophagitis, dilation of esophageal stricture, or surgery of the stomach or duodenum 3. Acute upper gastrointestinal bleeding or active gastric or duodenal ulcer within 30 days prior to the start of the follow-up period, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026